lapatinib has been researched along with Malignant Melanoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, BS; Farag, AK; Karam, R; Roh, EJ; Yoo, JS | 1 |
| Abdel-Fattah, MM; Amin, NH; El-Saadi, MT; Mohammed, AA; Said, EG | 1 |
| Abel, EV; Amaravadi, RK; Aplin, AE; Basile, KJ; Ertel, A; Fortina, P; Karakousis, GC; Kugel, CH; Le, K; Lee, JB; Schuchter, LM; Witkiewicz, AK; Xu, W; Xu, X | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Bekiranov, S; Capaldo, B; Conaway, MR; Gioeli, D; Mackey, AJ; Petricoin, EF; Roller, DG; Weber, MJ | 1 |
| Aurisicchio, L; Bedogni, B; Cappelletti, M; Lu, J; Pavoni, E; Roscilli, G; Thakur, V; White, WL | 1 |
| Agrawal, NS; Cronin, JC; Cruz, P; Lin, JC; Prickett, TD; Rosenberg, SA; Samuels, Y; Wei, X; Wunderlich, JR; Yates, KE | 1 |
| Burton, L; Chan, E; Fridlyand, J; Koeppen, H; Li, J; Lin, E; Merchant, M; Moffat, J; Neve, R; Peng, J; Penuel, E; Ribas, A; Settleman, J; Sosman, J; Sutherlin, DP; Wang, Y; Wilson, TR; Yan, Y | 1 |
8 other study(ies) available for lapatinib and Malignant Melanoma
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of pseudo-bicyclic pyrimidine-based compounds as potential EGFR inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lapatinib; Melanoma; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2022 |
Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Kidney Neoplasms; Lapatinib; Lung Neoplasms; Melanoma; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
Topics: Cell Survival; Enzyme Inhibitors; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Lapatinib; MAP Kinase Kinase Kinases; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-3; Signal Transduction; Skin Neoplasms; Sulfonamides; Transcription, Genetic | 2013 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Indoles; Lapatinib; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides | 2016 |
The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Melanoma; Mice; Mice, SCID; New Zealand; Polysaccharides; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Transcription Factor RelA; Undaria | 2017 |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; ErbB Receptors; Humans; Lapatinib; Melanoma; Mice; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-4; RNA Interference; Skin Neoplasms | 2009 |
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Ligands; Melanoma; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Vemurafenib | 2012 |